Completed PHASE3 INTERVENTIONAL 1-arm NCT01429116

Tasimelteon for the Treatment of Non-24-hour Sleep-Wake Disorder (N24HSWD) in Blind Individuals With no Light Perception

An Extension Open-Label Safety Study of a 24-month 20 mg Dose Regimen of Tasimelteon for the Treatment of Non-24-Hour Sleep-Wake Disorder (N24HSWD) in Blind Individuals With no Light Perception Who Have Enrolled in Other Tasimelteon Clinical Trials

Sponsor: Vanda Pharmaceuticals

Conditions Non-24-Hour Sleep-Wake Disorder

Interventions tasimelteon

Updated 7 times since 2017 Last updated: Apr 20, 2015 Started: Oct 31, 2011 Primary completion: Jan 31, 2015 Completion: Jan 31, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Non-24-Hour Sleep-Wake Disorder and is currently completed. Vanda Pharmaceuticals leads this study, which shows 7 recorded versions since 2011 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Oct 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Vanda Pharmaceuticals

Data source: Vanda Pharmaceuticals

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Ann Arbor, United States , Atlanta, United States , Boston, United States , Brandon, United States , Chesterfield, United States , Chevy Chase, United States , Columbia, United States , Denver, United States , Dublin, United States , Elk Grove Village, United States and 12 more locations